A dose prescription of 20 Gy in 5 fractions to WBRT and a SIB of 40. Gy in 5 fractions was prescribed in all cases. All patients had a corti- costeroid prescription ...
E100
International Journal of Radiation Oncology Biology Physics
primary and BM. All patients were stratified according with Graded Prognostic Assessment (GPA) with a median value of 2 (range 1-3.5). Mean BM metastases were 2 (range 1-6) and median Gross Tumor Volume Brain metastases (GTVBM) were 10.32 cc (range 0.06 e 59.52 cc). A dose prescription of 20 Gy in 5 fractions to WBRT and a SIB of 40 Gy in 5 fractions was prescribed in all cases. All patients had a corticosteroid prescription during treatment to prevent neurological symptoms. Results: We reported a good acute treatment tolerance and all patients completed radiation treatment without an increase in corticosteroid dose. Median follow-up was 5.4 months (range 1.8 e 16.5 months). Analyzing clinical outcomes at 3, 6 and 9 months we observed respectively: LC 100%, 88.9%, 76.2%, CNSC 88.5%, 81.7%, 54.5% and OS 83.8%, 61.6%, 51.3%. At Kaplan-Meier analyses patients with an age 65 years had a better OS (pZ0.025). A statistical trend was observed in patients with a control of systemic disease and OS (pZ0.1). At univariate and multivariate analysis we did not report any statistical difference. Conclusion: Preliminary analysis reported a good acute tolerance of the radiation treatment. Apparently patients younger than 65 years and with a control of systemic disease had better prognosis in terms of OS. A longer follow-up and inclusion of new patients are necessary. These preliminary results justified continuing the clinical study with the goal to establish the role of hypofractionated WBRT-SIB in patients with diagnosis of brain metastases. Author Disclosure: N. Giaj Levra: None. F. Moretto: None. A. Fiorentino: None. M. Levis: None. S. Fersino: None. E. Pelle: None. F. Ricchetti: None. R. Mazzola: None. F. Alongi: None. U. Ricardi: None.
population at risk for seizures may help guide rational use of anticonvulsant therapy. Author Disclosure: V. Jairam: None. V.L. Chiang: None. J.B. Yu: Research Grant; 21st Century Oncology.
2254 Prognostic Factors for Seizures After First Radiosurgical Treatment in Patients With Brain Metastases V. Jairam,1 V.L. Chiang,1 and J.B. Yu2; 1Yale University School of Medicine, New Haven, CT, 2Yale School of Medicine, New Haven, CT Purpose/Objective(s): The use of Stereotactic Radiosurgery (SRS) for the treatment of brain metastases is increasing. One of the side effects of SRS can be the induction of seizures both acutely and long-term. This study aims to investigate the incidence of seizures after SRS as well as factors that may predispose to seizure development after SRS. Materials/Methods: We queried our institutional SRS database for all SRS-treated patients with seizures and brain metastases. Demographic data, cancer and seizure-related clinical details, along with treatment and survival data were collected for all patients relative to their first SRS session even for patients undergoing multiple radiosurgical salvage treatments. Differences in seizure incidence were analyzed with c2, logistic regression, and independent samples t-tests. Results: We identified 929 patients who were treated between 1999 and 2014. The mean age was 61 (range 12-93). One hundred sixty-three patients (17.5%) reported seizures after radiosurgery. Factors predictive of post-SRS seizures included craniotomy prior to SRS (hazard ratio [HR] 2.21, p
